ReadMax—a novel reading and scoring approach for EGFR gene copy number to predict therapeutic benefit of erlotinib treatment in EGFR wild‐type non‐small‐cell lung cancer

Publisher： John Wiley & Sons Inc

E-ISSN： 2056-4538|1|3|134-143

ISSN： 2056-4538

Source： The Journal Of Pathology: Clinical Research, Vol.1, Iss.3, 2015-06, pp. : 134-143

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase II study of erlotinib for previously treated patients with EGFR wildtype nonsmallcell lung cancer, following EGFR mutation status reevaluation with the Scorpion Amplified Refractory Mutation System

By                      

Molecular and Clinical Oncology, Vol. 2, Iss. 6, 2014-01 ,pp. : 991-996

Spandidos Publications

Access to resources Recommend Favorite

Therapeutic cancer vaccines in the treatment of non-small-cell lung cancer

By Limacher Jean-Marc   Spring-Giusti Clémentine   Bellon Nadine   Ancian Philippe   Rooke Ronald   Bonnefoy Jean-Yves  

Expert Review of Vaccines, Vol. 12, Iss. 3, 2013-03 ,pp. : 263-270

Informa Healthcare

Access to resources Recommend Favorite

Erlotinib with pemetrexed/cisplatin for patients with EGFR wild-type lung adenocarcinoma with brain metastases

By              

Molecular and Clinical Oncology, Vol. 2, Iss. 3, 2014-01 ,pp. : 449-453

Spandidos Publications

Access to resources Recommend Favorite

Association of EGFR mutations with low BRCA1 gene expression in non-small cell lung cancer

By Li   Xie   Lai  

Molecular and Clinical Oncology, Vol. 1, Iss. 1, 2013-01 ,pp. : 195-199

Spandidos Publications

Access to resources Recommend Favorite

Cotargeting EGFR and autophagy signaling: A novel therapeutic strategy for nonsmallcell lung cancer (Review)

By              

Molecular and Clinical Oncology, Vol. 2, Iss. 1, 2014-01 ,pp. : 8-12

Spandidos Publications

Access to resources Recommend Favorite